Application Potential of Extracellular Vesicles Derived From Mesenchymal Stem Cells in Renal Diseases

Enhui Li1, Jia Xu1, Ning Liu1

  • 1Department of Nephrology, Xiangya Hospital, Central South University, Changsha, People's Republic of China.

Stem Cells (Dayton, Ohio)
|November 30, 2023
PubMed

Insights

Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) show promise for treating kidney diseases, offering advantages over stem cells. Further research into MSC-EVs is vital for clinical applications in nephrology.

Area of Science:

  • Nephrology
  • Regenerative Medicine
  • Biotechnology

Background:

  • Renal diseases present a significant global health burden with limited treatment options.
  • Current therapies for kidney diseases like acute kidney injury and chronic kidney disease primarily slow progression, rather than reverse damage.
  • There is a critical need to understand kidney disease mechanisms and identify novel therapeutic targets and drugs.

Purpose of the Study:

  • To provide a comprehensive overview of mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) in the context of kidney diseases.
  • To discuss the potential of MSC-EVs as a cell-free therapeutic strategy for renal pathologies.
  • To highlight the advantages of MSC-EVs over mesenchymal stem cells (MSCs) for therapeutic applications.

Main Methods:

  • Review of existing scientific literature on MSC-EVs and their application in kidney diseases.
  • Analysis of studies demonstrating the therapeutic effects and tissue localization of MSC-EVs.
  • Discussion of the comparative benefits of MSC-EVs, including preservation, immunogenicity, and modification.

Main Results:

  • MSC-EVs replicate the therapeutic benefits of MSCs and target damaged kidney tissue.
  • MSC-EVs possess advantages such as ease of preservation, low immunogenicity, and reduced tumor formation risk compared to MSCs.
  • Standardized methods for MSC-EV culture, isolation, purification, and drug delivery are crucial for clinical translation.

Conclusions:

  • MSC-EVs represent a promising cell-free therapeutic approach for various kidney diseases.
  • Further development of standardized protocols is essential to advance the clinical application of MSC-EVs in nephrology.
  • Understanding the detailed mechanisms and overcoming limitations of MSC-EVs will facilitate their use in treating renal diseases.

Related Concept Videos

Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.7K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.1K
Overview of Exosomes01:36

Overview of Exosomes

Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.7K